Compare Quest Diagnostics Inc (DGX) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs General Motors Company — how do they compare? Quest Diagnostics Inc trades at $231.12 (market cap $25.48B), while General Motors Company trades at $82.37 (market cap $72.17B). The key difference: General Motors Company is far larger — about 2.8× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and General Motors Company for 83 Days on average.
| DGX | GM | |
|---|---|---|
Market Cap | $25.48B | $72.17B |
Volume | 941,866 | 4,900,304 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $90.30 |
52-Week Low | $173.49 | $55.35 |
Typical Hold Time | 56 Days | 83 Days |
Enterprise Value | $31.23B | $175.15B |
Dividend Yield | 1.49% | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
General Motors (GM) trades at $80.99, down 1.24% amid broader auto sector weakness. The stock shows mixed signals with bearish technical indicators but strong analyst support (66.7% buy rating) and a $102.08 consensus price target. Recent Q3 2026 sales declined 5.5% due to EV weakness and discontinued models, though the company has beaten earnings estimates for three consecutive quarters. GM benefits from regulatory savings of $20.4B through 2031 from eased fuel economy rules.
GM faces near-term headwinds from declining vehicle sales and competitive pressure from Asian automakers, but maintains solid cash flow and attractive valuation metrics (P/S 0.42). The stock offers 26% upside to analyst targets, though profitability compression and market share losses present ongoing challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
